Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04666740 · ClinicalTrials.gov registry record · Phase 2
A Study of Pembrolizumab and Olaparib for People With Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency or Exceptional Treatment Response to Platinum-Based Therapy
A Phase 2 study of Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency (HRD), sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 63
- Enrollment target
- 7
- Study locations
NCT04666740: Active Phase 2 study of Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency (HRD), sponsored by Memorial Sloan Kettering Cancer Center.
NCT04666740 is a Phase 2 study of Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency (HRD) that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 63 participants, below the 181-participant average among 20 other Metastatic Pancreatic Ductal Adenocarcinoma trials with a reported enrollment target (65% lower). The trial reports 7 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04666740, a Phase 2 study of Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency (HRD), is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 63 participants
- Enrollment target
- 7
- Study locations
Study Summary
The study researchers think that combining the drugs pembrolizumab and olaparib (POLAR) may help people with this disease because pembrolizumab activates the immune system to fight cancer, and olaparib destroys cancer cells by preventing them from repairing damage to the genetic information that helps them survive and grow. The study researchers are doing this study to find out whether combining these drugs may be a more effective treatment for this cancer than taking olaparib alone.
Primary Outcome
PFS is defined as the time from the initiation of study treatment to radiographic progression or death.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Olaparib
Study Locations (7)
New York
- Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (All protocol activities) - Commack
- Memorial Sloan Kettering Westchester (All Protocol Activities) - Harrison
- Memorial Sloan Kettering Basking Ridge (All protocol activities) - New York
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Nassau (All protocol activities) - Rockville Centre
New Jersey
- Memorial Sloan Kettering Monmouth (All protocol activities) - Middletown
- Memorial Sloan Kettering Bergen (All protocol activities) - Montvale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2020-12-18 |
| Est. Completion | 2027-01 |
| Phase | Phase 2 |
What the registry record for NCT04666740 still lists
NCT04666740 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 63 participants, a relatively small participant target, below the 181-participant average among 20 other Metastatic Pancreatic Ductal Adenocarcinoma trials with a reported enrollment target (65% lower).
The record links to 2 conditions, with Metastatic Pancreatic Ductal Adenocarcinoma appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT04666740 lists 7 locations in 2 states (New York, New Jersey).
Frequently Asked Questions
What is clinical trial NCT04666740 about?
NCT04666740 is a clinical study titled "A Study of Pembrolizumab and Olaparib for People With Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency or Exceptional Treatment Response to Platinum-Based Therapy". The study researchers think that combining the drugs pembrolizumab and olaparib (POLAR) may help people with this disease because pembrolizumab activates the immune system to fight cancer, and olaparib destroys cancer cells by preventing them from repairing damage to the genetic information that hel...
What is the current status of trial NCT04666740?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 63 participants. The study started on 2020-12-18. Estimated completion is 2027-01.
What conditions does trial NCT04666740 study?
This clinical trial studies the following conditions: Metastatic Pancreatic Ductal Adenocarcinoma, Homologous Recombination Deficiency (HRD).
What interventions are being tested in trial NCT04666740?
The interventions under investigation include: Pembrolizumab (DRUG), Olaparib (DRUG).
Who is sponsoring clinical trial NCT04666740?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04666740 being conducted?
This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Pancreatic Ductal Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04666740's enrollment target sits among peer trials
63 10th of 20 higher than 11 of 20 other Metastatic Pancreatic Ductal Adenocarcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Pancreatic Ductal Adenocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation
RECRUITING · Phase 2
-
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
RECRUITING · Phase 2
-
Utility of ctDNA in Early Switch of First-line mFOLFIRINOX in Metastatic Pancreatic Ductal Adenocarcinoma
RECRUITING · Phase 2
-
A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Glipizide to Treat High Blood Sugar in People With Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 2
-
BXCL701 and Pembrolizumab in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03383575 · 63 participants · Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- NCT04870944 · 63 participants · Phase 1
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- NCT05031897 · 63 participants · Phase 2
Two Step Haplo With Radiation Conditioning
- NCT05312671 · 63 participants · Phase 2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI